KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 Diabetes. PMID 39475306 · Pharm Stat · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prospective Evaluation of Supplemental External Beam Radiation Therapy With Palladium-103 Prostate Brachytherapy: Long-Term Results of the 44/20/0 Trials. PMID 39447863 · Pract Radiat Oncol · 2025 The trial phase is not explicitly established as Phase III/IIIb or Phase II/III from the provided metadata, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials. PMID 39317165 · Digestion · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Application Value of Iodine-131 Combined with Levothyroxine Sodium in Patients with Differentiated Thyroid Cancer after Surgery. PMID 39307136 · Oncology · 2025 The study is a randomized, oncology trial with a drug intervention and primary results. However, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, recurrence-free survival with Kaplan-Meier/HR). The primary outcomes are treatment effectiveness rate, thyroglobulin levels, and recurrence rate at 1 year, but the recurrence analysis is not presented as a time-to-event (e.g., Kaplan-Meier curve or hazard ratio). Additionally, the phase is not explicitly stated as Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and pharmacokinetics of CPL-01, an investigational long-acting ropivacaine, in bunionectomy: Results of a phase 2b study. PMID 39303759 · J Foot Ankle Surg · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Controlled Trial of the Behavioral Intervention for Increasing Physical Activity in Multiple Sclerosis Project: Fidelity Monitoring and Outcomes. PMID 39287190 · Behav Med · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). PMID 39233006 · Pract Radiat Oncol · 2025 Record is excluded due to absence of a drug intervention and absence of a primary/key secondary time-to-event efficacy endpoint. The abstract reports on centralized quality assurance and treatment plan compliance for stereotactic body radiation therapy in a randomized trial, but does not present survival or time-to-event efficacy data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of SBRT plus immunotherapy on immune status and survival quality of NSCLC patients: A study of combined radiotherapy and immunotherapy. PMID 39177632 · Technol Health Care · 2025 The study is an original randomized trial in human oncology (NSCLC) with a drug-containing intervention (immunotherapy). However, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR data; outcomes are efficacy rates, tumor markers, immune cells, and quality-of-life scores (KPS). Furthermore, the phase is not specified as Phase III/IIIb or Phase II/III, and cannot be reliably inferred from the title, abstract, or metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Cerebral Oximetry-Guided Treatment on Brain Injury in Preterm Infants as Assessed by Magnetic Resonance Imaging at Term Equivalent Age: An Ancillary SafeBoosC-III Study. PMID 38934161 · Neonatology · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials. PMID 38908750 · Hellenic J Cardiol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
An exploration into the relationship between insomnia and repetitive negative thinking among cancer survivors. PMID 38831557 · J Psychosoc Oncol · 2025 This is a secondary analysis of a pilot randomized trial of non-drug CBT-I for insomnia in cancer survivors. It is not a Phase III or definitive randomized trial, does not involve a drug intervention, and reports no time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial. PMID 38615657 · Acta Haematol · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII. PMID 38599195 · Acta Haematol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rationale and Design of the Statin Use in Intracerebral Hemorrhage Patients (SATURN) Trial. PMID 38493765 · Cerebrovasc Dis · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
8-Aminoguanine and its actions in the metabolic syndrome. PMID 39349636 · Sci Rep · 2024-Sep-30 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment. PMID 39409958 · Cancers (Basel) · 2024-Sep-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. PMID 39343511 · J Immunother Cancer · 2024-Sep-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The iSEARCH randomised controlled trial protocol: a pragmatic Australian phase III clinical trial of intrapartum sildenafil citrate to improve outcomes potentially related to intrapartum hypoxia. PMID 39343454 · BMJ Open · 2024-Sep-28 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials. PMID 39457519 · Biomedicines · 2024-Sep-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
OPTimising MEDicine information handover after Discharge (OPTMED-D): protocol for development of a multifaceted intervention and stepped wedge cluster randomised controlled trial. PMID 39334438 · Trials · 2024-Sep-27 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA). PMID 39334260 · Trials · 2024-Sep-27 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. PMID 39321362 · N Engl J Med · 2024-Sep-26 Eligibility fails on oncology, randomization, and primary endpoint criteria. The study is a Phase III gene therapy trial for hemophilia B, not cancer. It is single-arm, not randomized. Its primary endpoint is a count-based rate (annualized bleeding rate), not a time-to-event or Kaplan-Meier outcome.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection. PMID 39321361 · N Engl J Med · 2024-Sep-26 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction to: Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir. PMID 39095060 · Clin Infect Dis · 2024-Sep-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. PMID 38985561 · Clin Infect Dis · 2024-Sep-26 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
RidStress 2 randomised controlled trial protocol: an Australian phase III clinical trial of intrapartum sildenafil citrate or placebo to reduce emergency caesarean birth for fetal distress in women with small or suboptimally grown infants at term (≥37 weeks). PMID 39322593 · BMJ Open · 2024-Sep-25 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Impacts of participation in surgical clinical trial on safety and survival outcomes in patients with right-sided colon cancer]. PMID 39313432 · Zhonghua Wei Chang Wai Ke Za Zhi · 2024-Sep-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy. PMID 39408601 · Int J Mol Sci · 2024-Sep-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Feasibility, safety and preliminary efficacy of preoperative stereotactic radiotherapy on the future pancreatic neck transection margin to reduce the risk of pancreatic fistula after high-risk pancreatoduodenectomy (FIBROPANC): protocol for a multicentre, single-arm trial. PMID 39317507 · BMJ Open · 2024-Sep-24 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A phase 2 study of a longitudinal multidimensional rehabilitation program for allogeneic blood and marrow transplantation patients. PMID 38985303 · Blood Adv · 2024-Sep-24 The trial is a phase 2 randomized controlled trial evaluating a rehabilitation program, not a drug intervention. It lacks a phase 3 designation and a time-to-event efficacy endpoint, which are required for eligibility.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies. PMID 39313302 · RMD Open · 2024-Sep-23 The report is a Phase III randomized controlled trial of a drug (bimekizumab) for psoriatic arthritis, which is an autoimmune/inflammatory condition, not a malignant neoplasm (oncology). While it is a human, randomized, phase III trial with a drug intervention and presents primary results, it fails the core 'oncology' criterion. Furthermore, the endpoints are patient-reported outcomes (pain, fatigue, function, quality of life), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. PMID 39313288 · BMJ Open · 2024-Sep-23 The record describes a qualitative study embedded in the SCOPE2 trial, not the primary or key secondary efficacy results of the randomized trial. The study explores patient experiences and quality of life, not time-to-event endpoints like OS or PFS. While the underlying SCOPE2 trial is randomized and oncology-focused, this specific publication does not report the trial's efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. PMID 39270686 · Lancet · 2024-Sep-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiograph accelerated detection and identification of cancer in the lung (RADICAL): a mixed methods study to assess the clinical effectiveness and acceptability of Qure.ai artificial intelligence software to prioritise chest X-ray (CXR) interpretation. PMID 39306349 · BMJ Open · 2024-Sep-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. PMID 39304797 · BMC Cancer · 2024-Sep-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer. PMID 39164816 · Chin Med J (Engl) · 2024-Sep-20 The record is a secondary analysis (genomic correlates) aggregating data from multiple phase 3 trials. It is not the original formal result report of a single randomized trial. The abstract focuses on identifying predictive biomarkers and does not explicitly report a time-to-event primary efficacy endpoint (e.g., OS/PFS with KM curves or HR) as the main result. Therefore, it does not meet the criteria for a primary efficacy report from a definitive randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. PMID 38760158 · BMJ Evid Based Med · 2024-Sep-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effectiveness of long-term low-dose aspirin in the prevention of gastric cancer after Helicobacter pylori eradication: study design and rationale of Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT). PMID 39300505 · Trials · 2024-Sep-19 This is a study design and rationale paper for a randomized trial, not a report of trial results. It describes a protocol without providing any efficacy data, phase is not explicitly stated, and the publication type is 'Clinical Trial Protocol'.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rapid normalization of vitamin D deficiency in PICU (VITdALIZE-KIDS): study protocol for a phase III, multicenter randomized controlled trial. PMID 39300483 · Trials · 2024-Sep-19 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. PMID 39300447 · J Hematol Oncol · 2024-Sep-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol. PMID 39300376 · BMC Cancer · 2024-Sep-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial. PMID 38871464 · Thorax · 2024-Sep-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF. PMID 39260929 · J Am Coll Cardiol · 2024-Sep-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. PMID 39037800 · JAMA · 2024-Sep-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial. PMID 38853036 · Vaccine · 2024-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Does stereotactic thrombolysis with alteplase for intracerebral haemorrhage alter intraventricular haematoma volume? A secondary analysis of the MISTIE-III trial. PMID 38670789 · J Neurol Neurosurg Psychiatry · 2024-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors- impact on breast adipose oxylipin and DNA methylation patterns. PMID 39371146 · medRxiv · 2024-Sep-16 The study is a randomized trial in breast cancer survivors but evaluates dietary n-3 fatty acid supplementation (not a drug) and reports biomarker/epigenetic outcomes, not time-to-event efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. PMID 39284697 · BMJ Open · 2024-Sep-16 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Occupational support following arthroplasty of the lower limb (OPAL): trial protocol for a UK-wide phase III randomised controlled trial. PMID 39284693 · BMJ Open · 2024-Sep-16 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative. PMID 38736319 · Cancer · 2024-Sep-15 The record is a secondary analysis of a large randomized dietary intervention trial. It does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial evaluating a specific drug intervention for efficacy, and the primary outcomes are epidemiological associations (incidence, mortality risk) rather than a formal time-to-event efficacy endpoint (e.g., OS, PFS) from a drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -